Genocea’s GEN-009 Clinical Results Presentation Selected by ASCO’s Journal of Clinical Oncology® as a Top 10 Featured Immuno-oncology Abstract

Poster presentation tomorrow, June 1^st at 8:00 am CT in Poster Hall A

Conference call and webcast to discuss results Monday, June 3^rd at 8:30 am ET

CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that the Journal of Clinical Oncology^® (An American Society of Clinical Oncology Journal) has selected the company’s GEN-009 clinical results presentation at the 2019 ASCO Annual Meeting as a top 10 featured abstract in immuno-oncology. The full poster will be available on the Genocea website here concurrent with its presentation tomorrow:

ASCO 2019 POSTER SESSION: Developmental Immunotherapy and Tumor Immunobiology
Poster Board: #255 • Abstract 2611

	Title:		A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses
	Presenters:		Roger B. Cohen, M.D., University of Pennsylvania Perelman School of Medicine and principal investigator in the trial, and Przemyslaw W. Twardowski, M.D., John Wayne Cancer Institute
	Date:		Saturday, June 1, 8:00 AM – 11:00 AM Central Time
	Location:		Hall A

Conference Call and Webcast – Monday, June 3^rd at 8:30 am ET
Genocea will host a conference call and webcast to discuss the clinical results presented at ASCO at 8:30 am ET on Monday, June 3, 2019. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 9068006. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

About Genocea Biosciences, Inc.
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit www.genocea.com